<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "adalimumab inj SYR">
<dose><value>10</value>
<value>15</value>
<value>20</value>
<value>25</value>
<value>30</value>
<value>35</value>
<value>40</value>
<value>160</value>
<value>80</value>
</dose>
<route><value>SC</value>
</route>
<strength><value>40 mg/0.8 mL</value>
</strength>
<frequency><value>ONCE</value>
<value>EVERY 2 WEEKS</value>
<value>DAILY</value>
</frequency>
<instruction><value>Administer for 2 days.</value>
</instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population></Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Patients identified as carriers of Hepatitis B virus should be monitored for signs/symptoms of relapse of HBV infection throughout therapy and several months following termination of therapy.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3607</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Disease-modifying Antirheumatic Agents</value>
</AHFSName>
<HighAlert></HighAlert>
</drug>